Abstract Number: 1411 • ACR Convergence 2025
Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
Background/Purpose: Treat to target management is recommended in psoriatic arthritis (PsA) to improve disease control and patient quality of life. Minimal disease activity (MDA) criteria…Abstract Number: 1400 • ACR Convergence 2025
Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease
Background/Purpose: Sjogren’s disease (SjD) is a systemic autoimmune disorder characterized by inflammatory involvement of the exocrine glands and extra-glandular manifestations. Among the latter, there is…Abstract Number: 1286 • ACR Convergence 2025
Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: The management of immune thrombocytopenia in childhood-onset systemic lupus erythematosus (cSLE) is not standardized. We examined the efficacy and safety of hydroxychloroquine (HCQ) as…Abstract Number: 1364 • ACR Convergence 2025
Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
Background/Purpose: Early rheumatoid arthritis (RA) is a critical therapeutic window where prompt treatment targeting remission or low disease activity can significantly reduce long-term disability and…Abstract Number: 1382 • ACR Convergence 2025
Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disorder primarily targeting exocrine glands. A significant extraglandular manifestation is interstitial lung disease (ILD), which contributes to…Abstract Number: 1362 • ACR Convergence 2025
Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by persistent synovial inflammation and progressive joint damage. Selecting an effective biologic therapy remains a…Abstract Number: 1420 • ACR Convergence 2025
A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease with systemic complications that may contribute to increased mortality risk. This study examines the characteristics and…Abstract Number: 1406 • ACR Convergence 2025
A Combined Score of Facet Joint Ankylosis and Syndesmophyte Development Correlates Well with Spinal Mobility in Axial Spondyloarthritis
Background/Purpose: In axial SpA (axSpA), the computed tomography (CT) syndesmophyte score (CTSS) has shown to capture more spinal structural damage progression and to better correlate…Abstract Number: 1300 • ACR Convergence 2025
International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
Background/Purpose: Consensus-derived treat-to-target (T2T) goals for childhood-onset SLE (cSLE), including clinical remission on low dose steroids (cCR), have been endorsed by the Paediatric Rheumatology European…Abstract Number: 1271 • ACR Convergence 2025
Overcoming Obstacles to Care: Survey of Adult Patients with Idiopathic Inflammatory Myopathies (IIM)
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogenous autoimmune diseases requiring coordinated, patient-centered care. Understanding patient perspectives on diagnosis, treatment, health screening, and barriers to care…Abstract Number: 1338 • ACR Convergence 2025
Short-Chain Fatty Acids and Their Gut Microbial Metabolic Pathways Distinguish Rheumatoid Arthritis in Discordant Monozygotic Twins
Background/Purpose: Although genetic factors have been identified in the pathogenesis of RA, the concordance rate in monozygotic (MZ) twins is low, suggesting that other factors…Abstract Number: 1440 • ACR Convergence 2025
Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis
Background/Purpose: We aimed to compare the demographic and clinical characteristics of the patients with axial spondyloarthritis (aSpA) receiving standard-dose versus tapered-dose biologic disease-modifying antirheumatic drugs…Abstract Number: 1433 • ACR Convergence 2025
Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort
Background/Purpose: The concept of Difficult-to-Manage Axial Spondyloarthritis (D2M-ax-SpA) was recently introduced by the Assessment of Spondyloarthritis International Society (ASAS). According to this new definition, D2M-ax-SpA…Abstract Number: 1424 • ACR Convergence 2025
Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis
Background/Purpose: Chronic pain is one of the common causes of disability in axial spondyloarthritis (axSpA). The mechanism behind this pain is not well understood, hindering…Abstract Number: 1310 • ACR Convergence 2025
Naturalized Language Processing Based Extraction of Rheumatoid Arthritis Disease Activity Measures from the Electronic Health Record
Background/Purpose: A treat-to-target approach in rheumatoid arthritis (RA) requires intense monitoring of RA disease activity with measures such as the clinical disease activity index (CDAI).…
- « Previous Page
- 1
- …
- 112
- 113
- 114
- 115
- 116
- …
- 2607
- Next Page »
